Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Horizon Therapeutics
Horizon Therapeutics
Activities:
Manufacturing
Ingredients
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Regulatory
Horizon Pharma to leverage Medidata Clinical Cloud and eTMF
Medidata will increase efficiency for Horizon Pharma by managing its clinical research on a unified cloud platform
Finance
Horizon Pharma pursues Depomed with US$3bn hostile bid
Aims to combine its rare disease business with Depomed's pain treatments
Finance
Horizon Pharma to purchase Hyperion Therapeutics for US$1.1bn
Expands orphan drug business with the addition of two treatments for rare metabolic conditions
Finance
Horizon Pharma to buy Vidara Therapeutics International for US$660m
US company aims to take advantage of lower tax rates in Ireland
Subscribe now